This website is intended for U.S. residents 18 years of age or older.
ZEPOSIA® (ozanimod) is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.
It is not known if ZEPOSIA is safe and effective in children.
ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
It is not known if ZEPOSIA is safe and effective in children.
For your medication:
For your medical costs:
Your UC Nurse Navigator can help you better understand your costs and what financial support options are available to you.†
†
While Nurse Navigators can answer questions about ZEPOSIA, please talk to your healthcare provider for medical advice.
As the COVID-19 situation continues to evolve,
If you’ve lost your job or health insurance coverage because of the
Your
insurance provider. Your UC Nurse Navigator and a team of experts can help you understand what those costs will be (and if you're eligible for
the co-pay savings offer).* View
co-pay terms & conditions.
*
While Nurse Navigators can answer questions about ZEPOSIA, please talk to your healthcare provider for medical advice.
Eligible patients may pay as little
as $0 a month for ZEPOSIA.
View co-pay terms & conditions.
Before starting ZEPOSIA, you may need three medical tests that can be done at a healthcare provider’s office or at your home (for eligible patients)‡:
There may be costs associated with some of the routine medical tests, but depending on where these tests take place, eligible patients may qualify for reimbursement or incur no costs at all.†
If you accrue any costs associated with office visits (co-pay) or routine medical tests when starting ZEPOSIA, here’s what to do:
If you have private or commercial insurance and are experiencing delays or issues with coverage, the ZEPOSIA Bridge Program may be able to provide ZEPOSIA to you for free, as needed, until these issues are resolved (for up to 24 months).§
†
ZEPOSIA Co-pay Program is valid only for patients with commercial insurance. The Program includes a prescription benefit offer for out-of-pocket drug costs and a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam where the full cost is not covered by patient’s insurance. Patients are not eligible for the prescription benefit offer if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs. Patients are not eligible for the medical assessment benefit offer if they have insurance coverage for their prescription or medical assessment through a state or federal healthcare program, or reside in Massachusetts, Minnesota or Rhode Island. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. Patient must be 18 years of age or older. Patients may pay as little as $0 in out-of- pocket costs per prescription, subject to a maximum benefit of $18,000 during a calendar year. Patients may pay as little as $0 in out-of-pocket costs for the medical assessment, subject to a maximum benefit of $2,000. The medical benefit offer only applies to clinical baseline assessment services covered by the Program. Patients are responsible for any costs that exceed the maximum amounts. To receive the medical assessment benefit, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made. The Program expires on December 31, 2023. All Program payments are for the benefit of the patient only. Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the prescription or medical assessment benefit received by the patient through this Program. Patient’s acceptance of any Program benefit confirms that it is consistent with patient’s insurance and that patient will report the value received as may be required by his/her insurance provider. Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills. The Program is not insurance. Other limitations may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.
‡
Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patient must be new to therapy and have not previously received a sample or filled a prescription for ZEPOSIA. Patient is responsible for applicable taxes, if any. This offer is limited to one use per patient per lifetime and is non-transferable. Cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions permitted. Patients, pharmacists, and prescribers cannot seek reimbursement for the ZEPOSIA Free Trial from health insurance or any third party, including state or federally funded programs. Patients may not count the ZEPOSIA Free Trial as an expense incurred for purposes of determining out-of-pocket costs for any plan, including Medicare Part D true out-of-pocket costs (TrOOP). Offer is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law or restricted. The program is not insurance. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this offer at any time without notice.
§
The Bridge Program is available at no cost for eligible, commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments). The Bridge Program is not available to patients who have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs and is available for no more than 12 months to patients in MA, MN, and RI. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the program. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during program participation. Offer is not health insurance. Once coverage is approved by the patient’s commercial insurance plan, the patient will no longer be eligible. Void where prohibited by law, taxed, or restricted. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.
This type of insurance is usually provided by an employer or a union, or purchased directly from an insurance company.
If you have Medicare
When covered, people who have prescription insurance through Medicare may pay $0 to $2,424 per month for ZEPOSIA.
Your costs are determined by your pharmacy coverage, such as Medicare Part D, Medicare Advantage (Part C), by your coverage phase, and your income level. Use this link to learn about costs for Medicare drug coverage.
Certain patients may be eligible for Low-Income Subsidy, also known as “Extra Help.” Use this link to learn more.
Your
*
While Nurse Navigators can answer questions about ZEPOSIA, please talk to your healthcare provider for medical advice.
If you have Medicaid
When covered, people with Medicaid may pay $0 to $20 per month for ZEPOSIA. To find out if you qualify for Medicaid, or to get more information about
If you need further financial assistance, your UC Nurse Navigator can help you by identifying third-party charitable foundations that may be able to assist you.
Before starting ZEPOSIA, you may have three medical tests that can be done at a healthcare provider’s office:
Regardless of where these appointments take place, you will pay what you normally would for an in-network office visits and/or tests.
These are government-sponsored health insurance programs.
If you do not have prescription drug coverage or your insurance does not cover ZEPOSIA, you can expect to pay the list price for ZEPOSIA of $10,091 for the ZEPOSIA Starter Kit (the initial 37-day supply) or $8,182 for a 30-day supply of the regular daily dosage of ZEPOSIA per month, with any additional pharmacy charges or discounts based on where you purchase your medicine.
If you’re uninsured or underinsured, and need assistance with co-pay or ZEPOSIA treatment costs, please reach out to a UC Nurse Navigator to learn about the options available to you.*
*
While Nurse Navigators can answer questions about ZEPOSIA, please talk to your healthcare provider for medical advice.
This means you do not have health insurance or your insurance doesn’t cover treatment with ZEPOSIA.
Those who are eligible may
pay as
little as $0 a month
for ZEPOSIA
with a
co-pay savings offer. View
co-pay terms & conditions.
Sign up for ZEPOSIA 360
SupportTM to receive
resources,
information, and
support for
starting and
staying on
treatment.
*
ZEPOSIA Co-pay Program is valid only for patients with commercial insurance. The Program includes a prescription benefit offer for out-of-pocket drug costs and a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam where the full cost is not covered by patient’s insurance. Patients are not eligible for the prescription benefit offer if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs. Patients are not eligible for the medical assessment benefit offer if they have insurance coverage for their prescription or medical assessment through a state or federal healthcare program, or reside in Massachusetts, Minnesota or Rhode Island. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. Patient must be 18 years of age or older. Patients may pay as little as $0 in out-of-pocket costs per prescription, subject to a maximum benefit of $18,000 during a calendar year. Patients may pay as little as $0 in out-of-pocket costs for the medical assessment, subject to a maximum benefit of $2,000. The medical benefit offer only applies to clinical baseline assessment services covered by the Program. Patients are responsible for any costs that exceed the maximum amounts. To receive the medical assessment benefit, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made. The Program expires on December 31, 2023. All Program payments are for the benefit of the patient only. Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the prescription or medical assessment benefit received by the patient through this Program. Patient’s acceptance of any Program benefit confirms that it is consistent with patient’s insurance and that patient will report the value received as may be required by his/her insurance provider. Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills. The Program is not insurance. Other limitations may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.
You may be able
to save on ZEPOSIA
Collapse
Do not take ZEPOSIA if you:
Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.
ZEPOSIA may cause serious side effects, including:
Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:
Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.
Progressive multifocal leukoencephalopathy (PML). ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.
Call your healthcare provider if you experience the following symptoms of slow heart rate:
Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.
Continue reading for additional possible serious side effects of ZEPOSIA.
Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using ZEPOSIA with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:
You should not receive live vaccines during treatment with ZEPOSIA, for at least 1 month before taking ZEPOSIA and for 3 months after you stop taking ZEPOSIA. Vaccines may not work as well when given during treatment with ZEPOSIA.
ZEPOSIA can cause serious side effects, including:
The most common side effects of ZEPOSIA can include:
These are not all of the possible side effects of ZEPOSIA. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 1-800-FDA-1088.
Multiple Sclerosis (MS): ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Ulcerative Colitis (UC): ZEPOSIA is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.
It is not known if ZEPOSIA is safe and effective in children.
Please see full Prescribing Information, including Medication Guide.
Do not take ZEPOSIA if you:
Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.
ZEPOSIA may cause serious side effects, including: